Physicians' Academy for Cardiovascular Education

ACS

Effects of intensive lipid lowering on coronary plaque characteristics

10' education - Oct. 24, 2022 - Prof. Lorenz Räber, MD, PhD & Prof. Stephen Nicholls, MD

What is the best timing for P2Y12i cessation prior to CABG in patients with ACS?

3' education - Nov. 13, 2021 - Derek So, MD

Time to previous ACS event has no effect on efficacy of colchicine

5' education - Oct. 14, 2021 - Tjerk Opstal, MD

Combination therapy with PCSK9 mAbs in post-MI patients

10' education - Sep. 22, 2021 - Derek Connolly, MD, PhD - Online CME

12-Months follow up of rapid hs -TnT protocol in ACS suspected patients

5' education - May 16, 2021 - Prof. Derek Chew, MD, PhD

Personalized antithrombotic therapy after PCI

5' education - Mar. 17, 2021 - Niels van der Sangen, MD

Updates in the 2019 ESC/EAS guidelines for the management of dyslipidemia

10' education - Sep. 29, 2020 - Prof. François Mach, MD

Stopping with aspirin after 3 months DAPT is safe in a wide range of patients

3' education - Apr. 2, 2020 - Prof. Freek Verheugt, MD

Effect of BET inhibition on CV outcomes in ACS and diabetes patients

10' education - Dec. 9, 2019 - Prof. Kausik Ray, MD

Hs-troponin measured 30 min after admission to diagnose MI

5' education - Oct. 24, 2019 - Paris, France - Camilla Bang, MD

Sex-related differences in ACS patients

5' education - Oct. 15, 2019 - Paris, France - Sanne Peters, PhD

Clinical update on BET inhibition: The patient profile that may benefit from BET inhibition

10' education - Aug. 31, 2019 - Prof. Kausik Ray, MD

The 2019 ESC/EASD diabetes guidelines: a major paradigm shift in the management of T2DM

10' education - Sep. 30, 2019 - Paris, France - Prof. Francesco Cosentino, MD

Reduced long-term CV death and MI with complete multivessel revascularization in STEMI

3' education - Sep. 25, 2019 - Paris, France - Prof. Shamir Mehta

Insights and lessons from the ODYSSEY Outcomes trial: Which patients benefit most?

10' education - Sep. 28, 2019 - Paris, France - Prof. Ph. Gabriel Steg, MD - Online CME

Reduced LDL-c with PCSK9 inhibitor in acute setting of ACS

5' education - Aug. 31, 2019 - Paris, France - Prof. François Mach

No beneficial effects of oxygen use in subjects with a heart attack

3' education - Sep. 2, 2019 - ESC 2019, Paris - Prof. Ralph Stewart, New Zealand

A one-hour hs-troponin protocol in ACS suspected patients resulted in more rapid discharge

3' education - Sep. 3, 2019 - Prof. Derek Chew

Reduction in bleeding with genotype-guided strategy for choice of P2Y12i in STEMI patients

3' education - Sep. 3, 2019 - Danny Claassens

Head-to-head comparison of P2Y12-inhibitors in ACS yields surprising results

3' education - Sep. 1, 2019 - Paris, France - Prof. Stefanie Schüpke

Major benefits with implementation of rapid rule-out pathway for MI

3' education - Sep. 1, 2019 - Prof. Nicholas Mills

Challenges for screening and treatment of FH patients in clinical cardiology

5' education - Feb. 13, 2019 - Kausik Ray, Kees Hovingh - Online CME

Better outcomes in patients with AF and ACS/PCI with NOAC vs. VKA and when dropping aspirin

3' education - Mar. 17, 2019 - New Orleans, LA, USA - John Alexander, MD

Neutral outcomes for early intervention strategy compared to standard strategy in NSTEMI patients

3' education - Aug. 28, 2018 - Prof. Thomas Engstrom, Copenhagen, Denmark

P2Y12 inhibitor monotherapy for 23 months after 1 month of DAPT, compared to traditional 12-month DAPT

3' education - Aug. 27, 2018 - Prof. Patrick Serruys, Rotterdam, The Netherlands

Treatment with statin before PCI intervention reduces MACE in patients with ACS

3' education - Mar. 11, 2018 - ACC 2018, Orlando, FL, VS - Otavio Berwanger - São Paulo, Brasil

Results ODYSSEY OUTCOMES study can change clinical practice for treatment of high-risk ACS patients

3' education - Mar. 10, 2018 - ACC 2018, Orlando, FL, USA - Dr. Valentin Fuster, New York, NY, USA

Treatment of patients on oral anticoagulation who present with ACS

10' education - Sep. 15, 2017 - Dr. Jur ten Berg - Cardiologist, Nieuwegein, The Netherlands
##SCROLLER_ITEMS_FULL_TITLE##

Customising therapy approach in ACS based on underlying pathology seems promising

3' education - Oct. 21, 2016 - ESC - 2016 Rome - Ik-Kyung Jang, MD - Massachusetts General Hospital, Boston, MA, USA

No added value of monitoring platelet function after ACS

3' education - Oct. 6, 2016 - ESC - 2016 Rome - Stefan Gielen, MD - University of Leipzig, Germany

Effects of intensive lipid lowering on coronary plaque characteristics

10' education - Oct. 24, 2022 - Prof. Lorenz Räber, MD, PhD & Prof. Stephen Nicholls, MD
Prof. Räber and Prof. Nicholls discuss the results and implications of the PACMAN-AMI study, that investigated the effect of PCSK9i alirocumab on top of high-intensity statins on coronary plaque characteristics in patients with acute MI.

Prof. Räber and Prof. Nicholls discuss the results and implications of the PACMAN-AMI study, that investigated the effect of PCSK9i alirocumab on top of high-intensity statins on coronary plaque characteristics in patients with acute MI.

Nearly all ACS patients reach LDL-c goal when PCSK9i is added to optimal statin therapy

Literature - June 28, 2022 - Landmesser U, et al. - Eur J Prev Cardiol. 2022

In a subanalysis of the ODYSSEY OUTCOMES trial, 95% of patients with recent acute coronary syndrome (ACS) achieved LDL-c <1.4 mmol/L when alirocumab was added to optimal statin therapy, instead of only 17% with placebo.

Elevated sLOX-1 levels in ACS patients predict fatal events at 1 year

Literature - May 11, 2022 - Kraler S, et al. - Eur Heart J. 2022

Elevated plasma sLOX-1 levels –observed during acute coronary syndromes (ACS) – predict fatal events beyond both established CV risk factors and the updated GRACE score, in the multicenter SPUM-ACS study.

Higher sensitivity and NPV with the ESC 0/1-hour and 0/2-hour algorithms for acute MI

Literature - Mar. 9, 2022 - Chiang C-H, et al. - Ann Intern Med 2022

In a meta-analysis of 32 studies with 30,066 patients, the ESC 0/1-hour and 0/2-hour algorithms had higher sensitivities and negative predictive values (NPVs) for the triage of patients with suspected acute MI than the ESC 0/3-hour algorithm.

Improved outcomes with DOAC in AF and ACS and/or PCI independent of bleeding and stroke risk

Literature - Feb. 10, 2022 - Harskamp RE, et al. - J Am Coll Cardiol 2022

No significant interaction was found on treatment effect of apixaban vs. VKA or aspirin vs. placebo across HAS-BLED or CHA2DS-VASc categories in patients with AF in the first 6 months following an ACS and/or PCI, in a post hoc analysis of the AUGUSTUS trial.

No reduction of MACE with PCSK9i in patients with a history of HF

Literature - Jan. 25, 2022 - White HD, et al. - Eur Heart J 2021

Although alirocumab reduced LDL-c in patients with or without a history of HF, alirocumab reduced MACE only in patients without HF and not in patients with a history of HF, in an analysis of ODYSSEY OUTCOMES.

A guided selection of P2Y12i therapy in ACS patients has most favorable profile

Literature - Jan. 17, 2022 - Galli M, et al. - Eur Heart J 2021
A network meta-analysis of 15 RCTs shows that a guided selection of P2Y12 inhibiting therapy using platelet function or genetic testing is the only strategy associated with a reduction of ischemic events without a trade-off in bleeding in patients with ACS.

A network meta-analysis of 15 RCTs shows that a guided selection of P2Y12 inhibiting therapy using platelet function or genetic testing is the only strategy associated with a reduction of ischemic events without a trade-off in bleeding in patients with ACS.

What is the best timing for P2Y12i cessation prior to CABG in patients with ACS?

3' education - Nov. 13, 2021 - Derek So, MD
The RAPID CABG trial randomized ACS patients who required non-emergent CABG to early vs. delayed surgery after ticagrelor cessation. Derek So shares the results of this trial.

AHA 2021 The RAPID CABG trial randomized ACS patients who required non-emergent CABG to early vs. delayed surgery after ticagrelor cessation. Derek So shares the results of this trial.

Randomized trial on early vs. delayed CABG after P2Y12i cessation in patients with ACS

News - Nov. 13, 2021

AHA 2021 This small, randomized study in patients with ACS who required non-emergent CABG showed no increased perioperative bleeding risk when ticagrelor was stopped 2-3 days compared to 5-7 days before surgery.

Time to previous ACS event has no effect on efficacy of colchicine

5' education - Oct. 14, 2021 - Tjerk Opstal, MD
Trials with colchicine included different CVD patients; post-MI or with chronic coronary disease. Tjerk Opstal and colleagues investigated whether the efficacy of colchicine was dependent of the time to previous ACS event.

Trials with colchicine included different CVD patients; post-MI or with chronic coronary disease. Tjerk Opstal and colleagues investigated whether the efficacy of colchicine was dependent of the time to previous ACS event.

Benefit of colchicine independent of timing of prior ACS

Literature - Sep. 27, 2021 - Opstal TSJ, et al. - JACC 2021
Efficacy of colchicine compared to placebo in patients with stable coronary disease in the LoDoCo2 trial was consistent irrespective of history and timing of prior ACS.

Efficacy of colchicine compared to placebo in patients with stable coronary disease in the LoDoCo2 trial was consistent irrespective of history and timing of prior ACS.

Combination therapy with PCSK9 mAbs in post-MI patients

10' education - Sep. 22, 2021 - Derek Connolly, MD, PhD - Online CME
Why should combination therapy, including PCSK9 monoclonal antibodies, be given to ACS patients? Derek Connolly sums up the evidence.

Why should combination therapy, including PCSK9 monoclonal antibodies, be given to ACS patients? Derek Connolly sums up the evidence. With question to test your knowledge.